Physician-scientist David Scheinberg discussed his discovery of a unique monoclonal antibody, a molecule that can be engineered to target specific proteins on cancer cells. The new monoclonal antibody, called ESK1, is different because it is capable of recognizing the presence of a protein inside cancer cells, not just on the surface.
Surgical pathologist Jorge Reis-Filho commented on a study that found that an experimental blood test could help identify whether women with advanced breast cancer are responding to treatment.
Memorial Sloan-Kettering’s Green Team, a committee established in 2009 to identify opportunities to reduce waste and conserve resources, effectively reduced energy costs in operating rooms by disabling air exchanges when the rooms are not in use.
Epidemiologist Colin Begg commented on a study that suggests that cancer patients on clinical trials may survive longer due to factors other than the treatment being studied.
Adam Cohen, Memorial Sloan-Kettering’s Assistant General Counsel and Manager of Immigration Services, commented on a report that found that more than 40 percent of the cancer researchers at America’s top cancer institutes are immigrants.
Deputy Physician-in-Chief for Clinical Research Paul Sabbatini commented on the ways targeted drugs are able to move through the approval process more quickly than other types of drugs.
Hematologist-oncologist Sergio Giralt was featured on this special episode of 20/20 that took viewers on a journey inside Good Morning America co-host Robin Roberts’s fight against myelodysplastic syndrome. Robin received a stem cell transplant to treat her disease at Memorial Sloan-Kettering.
Good Morning America co-host Robin Roberts discussed her return to the program after receiving a stem cell transplant at Memorial Sloan-Kettering with hematologist-oncologist Sergio Giralt, who led her treatment team. Her nurses were also featured on the program.
The Breakthrough Prize in Life Sciences – a new award established by Art Levinson, Sergey Brin, Anne Wojcicki, Mark Zuckerberg, Priscilla Chan, and Yuri Milner – was awarded to physician-scientist Charles Sawyers.
Gynecologic oncologist Martee Hensley discussed the importance of fundraising events like Cycle for Survival, which raises money for rare cancer research at Memorial Sloan-Kettering.
Visible Ink founder Judith Kelman discussed the Memorial Sloan-Kettering program she runs that connects patients with experienced writers, editors, and teachers to help them tell their stories in writing.
Medical oncologist Michael Morris commented on a study that found that men with high-risk prostate cancer treated with only 18 months of hormone therapy live just as long as those treated for a standard 36 months.
Medical oncologists Mark Kris and Larry Norton and cancer biologist Joan Massagué discussed a revolution currently taking place in cancer care – tailoring treatments for specific individuals based on their tumor’s molecular makeup.
